An Open-label Study to Assess the Safety and Tolerability of JANUVIA (Sitagliptin) in 30 Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck & Co
- 17 Dec 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 03 Feb 2010 Planned initiation date changed from 1 Jan 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.